Shares of Sarepta (SRPT) are down this morning, potentially due to the latest FDA Adverse Event Reporting System update on Elevidys, which ...
The stock is down 1% to $116.14 after hitting $113.38 earlier in the morning.Invest with Confidence: Follow TipRanks' Top Wall Street Analysts ...
Top-line Phase 3 trial data show ambulatory boys with Duchenne continued with motor improvements two years after a single ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback